非小细胞肺癌中RET融合的研究进展
Research Progress on RET Fusion in Non-Small-Cell Lung Cancer.
作者信息
Zhao Lu, Mei Qingyun, Yu Yongchao, Wang Na, Zhang Dou, Liao Dongying, Zuo Jinhui, Xie Hongxia, Jia Yingjie, Kong Fanming
机构信息
Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.
National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China.
出版信息
Front Oncol. 2022 May 30;12:894214. doi: 10.3389/fonc.2022.894214. eCollection 2022.
Abstract
Great progress has been made in the treatment of driver gene-positive Non- Small Cell Lung Cancer (NSCLC) in recent years. RET fusion was seen in 0.7% to 2% of NSCLC and was associated with younger age and never-smoker status. The pralsetinib and selpercatinib for RET fusion NSCLC was recommended by the 2021 NSCLC treatment guidelines. This review outlines the research progress in the treatment of RET fusion NSCLC, identifies current challenges and describes proposals for improving the outlook for these patients.
摘要
近年来，驱动基因阳性非小细胞肺癌（NSCLC）的治疗取得了巨大进展。RET融合在0.7%至2%的NSCLC中可见，且与较年轻的年龄和从不吸烟的状态相关。2021年NSCLC治疗指南推荐了普拉替尼和塞普替尼用于治疗RET融合的NSCLC。本综述概述了RET融合NSCLC治疗的研究进展，确定了当前面临的挑战，并描述了改善这些患者预后的建议。
相似文献
1
Research Progress on RET Fusion in Non-Small-Cell Lung Cancer.非小细胞肺癌中RET融合的研究进展
Front Oncol. 2022 May 30;12:894214. doi: 10.3389/fonc.2022.894214. eCollection 2022.
2
An overview of the role of selpercatinib and pralsetinib in RET-fusion-positive non-small cell lung cancer (NSCLC).塞尔帕替尼和普拉替尼在 RET 融合阳性非小细胞肺癌（NSCLC）中的作用概述。
J Oncol Pharm Pract. 2023 Mar;29(2):450-456. doi: 10.1177/10781552221147500. Epub 2022 Dec 26.
3
The budget impact of adding pralsetinib to a US health plan formulary for treatment of non-small cell lung cancer and thyroid cancer with alterations.将普拉替尼纳入美国医疗计划处方集用于治疗伴有特定改变的非小细胞肺癌和甲状腺癌的预算影响。
J Manag Care Spec Pharm. 2022 Feb;28(2):218-231. doi: 10.18553/jmcp.2021.21308. Epub 2021 Nov 2.
4
Pralsetinib: A Review in Advanced RET Fusion-Positive NSCLC.普拉替尼：治疗晚期 RET 融合阳性 NSCLC 的研究进展。
Drugs. 2022 May;82(7):811-816. doi: 10.1007/s40265-022-01720-4. Epub 2022 May 19.
5
Case report: First evidence of impressive efficacy of modulated dose selpercatinib in a young Caucasian with ANK3-RET fusion-positive NSCLC.病例报告：在一名患有ANK3-RET融合阳性非小细胞肺癌的年轻白种人中，首次证明了调整剂量的塞尔帕替尼具有显著疗效。
Front Oncol. 2024 Feb 7;14:1307458. doi: 10.3389/fonc.2024.1307458. eCollection 2024.
6
LIBRETTO-431: Confirming the Superiority of Selpercatinib to Chemotherapy and the Lack of Efficacy of Immune Checkpoint Inhibitors in Advanced Fusion-Positive (+) NSCLC, Another Unique Never-Smoker Predominant Molecular Subtype of NSCLC.LIBRETTO-431：证实塞尔帕替尼对比化疗的优越性以及免疫检查点抑制剂在晚期融合阳性（+）非小细胞肺癌（NSCLC）中的无效性，NSCLC的另一种独特的以从不吸烟者为主的分子亚型
Lung Cancer (Auckl). 2024 May 23;15:75-80. doi: 10.2147/LCTT.S460147. eCollection 2024.
7
Targeted therapy of RET fusion-positive non-small cell lung cancer.RET融合阳性非小细胞肺癌的靶向治疗
Front Oncol. 2022 Dec 13;12:1033484. doi: 10.3389/fonc.2022.1033484. eCollection 2022.
8
Therapeutic Advances in the Management of Patients with Advanced RET Fusion-Positive Non-Small Cell Lung Cancer.晚期 RET 融合阳性非小细胞肺癌患者治疗的进展。
Curr Treat Options Oncol. 2021 Jun 24;22(8):72. doi: 10.1007/s11864-021-00867-8.
9
A Metastatic Pulmonary Sarcomatoid Carcinoma Patient Harboring Fusion Responds to First-Line Pralsetinib Treatment: A Case Report.一名携带融合基因的转移性肺肉瘤样癌患者对一线普拉替尼治疗有反应：病例报告
Cancer Manag Res. 2023 Jul 26;15:765-769. doi: 10.2147/CMAR.S414077. eCollection 2023.
10
The efficacy and safety of selective RET inhibitors in RET fusion-positive non-small cell lung cancer: a meta-analysis.选择性RET抑制剂在RET融合阳性非小细胞肺癌中的疗效与安全性：一项荟萃分析。
Invest New Drugs. 2023 Oct;41(5):768-776. doi: 10.1007/s10637-023-01390-3. Epub 2023 Aug 21.
本文引用的文献
1
The clinical significance of RET gene fusion among Chinese patients with lung cancer.RET基因融合在中国肺癌患者中的临床意义。
Transl Cancer Res. 2020 Oct;9(10):6455-6463. doi: 10.21037/tcr-20-754.
2
Pralsetinib for the treatment of non-small cell lung cancer.普拉替尼治疗非小细胞肺癌。
Drugs Today (Barc). 2021 Sep;57(9):559-569. doi: 10.1358/dot.2021.57.9.3306764.
3
A Novel Oncogenic RET Fusion Variant in NSCLC: RELCH-RET.非小细胞肺癌中的一种新型致癌性RET融合变体：RELCH-RET
J Thorac Oncol. 2021 Oct;16(10):e95. doi: 10.1016/j.jtho.2020.12.018.
4
RET Inhibitors in Non-Small-Cell Lung Cancer.非小细胞肺癌中的RET抑制剂
Cancers (Basel). 2021 Sep 1;13(17):4415. doi: 10.3390/cancers13174415.
5
Precision therapy for RET-altered cancers with RET inhibitors.使用 RET 抑制剂治疗 RET 改变的癌症的精准疗法。
Trends Cancer. 2021 Dec;7(12):1074-1088. doi: 10.1016/j.trecan.2021.07.003. Epub 2021 Aug 12.
6
Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations.抗PD1/PD-L1免疫疗法治疗具有可操作致癌驱动基因突变的非小细胞肺癌
Int J Mol Sci. 2021 Jun 11;22(12):6288. doi: 10.3390/ijms22126288.
7
A Pilot Study of Preoperative Vandetanib on Markers of Proliferation and Apoptosis in Breast Cancer.术前凡德他尼对乳腺癌增殖和凋亡标志物的初步研究。
Am J Clin Oncol. 2021 Sep 1;44(9):456-462. doi: 10.1097/COC.0000000000000845.
8
Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program.塞尔帕替尼治疗RET融合阳性非小细胞肺癌（SIREN）：一项通过准入计划治疗患者的回顾性分析
Ther Adv Med Oncol. 2021 Jun 11;13:17588359211019675. doi: 10.1177/17588359211019675. eCollection 2021.
9
Therapeutic Advances in the Management of Patients with Advanced RET Fusion-Positive Non-Small Cell Lung Cancer.晚期 RET 融合阳性非小细胞肺癌患者治疗的进展。
Curr Treat Options Oncol. 2021 Jun 24;22(8):72. doi: 10.1007/s11864-021-00867-8.
10
Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study.普拉替尼治疗 RET 融合阳性非小细胞肺癌（ARROW）：多队列、开放标签、1/2 期研究。
Lancet Oncol. 2021 Jul;22(7):959-969. doi: 10.1016/S1470-2045(21)00247-3. Epub 2021 Jun 9.
Zotero 插件